Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AB928 + IPI-549 + Pegylated liposomal-doxorubicin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB928 | AB 928|AB-928|Etrumadenant | Adenosine Targeting 16 | AB928 (etrumadenant) is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and lead to enhanced anti-tumor activity in combination with other agents (European Journal of Cancer, Vol 92, S14-S15, PMID: 30569245). | |
IPI-549 | IPI 549|IPI549 | PIK3CG inhibitor 8 | IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029, PMID: 32194211). | |
Pegylated liposomal-doxorubicin | Doxil | ATI-0918|CAELYX | Chemotherapy - Anthracycline 11 | Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03719326 | Phase I | AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | Active, not recruiting | USA | 1 |